Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23198919 | 0.90 | PDCD1 (0.73) | PDCD1CD274 | |
| SCHEMBL29983829 | 0.90 | PDCD1 (0.73) | PDCD1CD274 | |
| SCHEMBL25610075 | 0.90 | PDCD1 (0.73) | PDCD1CD274 | |
| SCHEMBL26331281 | 0.83 | CD274 (1.00) | PDCD1CD274 | |
| SCHEMBL21290781 | 0.83 | CD274 (1.00) | PDCD1CD274 | |
| SCHEMBL31354032 | 0.83 | PDCD1 (0.84) | PDCD1CD274 | |
| Evixapodlin SCHEMBL21290636 | 0.83 | PDCD1 (1.00) | PDCD1CD274 | |
| Evixapodlin SCHEMBL21290535 | 0.83 | PDCD1 (1.00) | PDCD1CD274 | |
| Evixapodlin SCHEMBL21274280 | 0.83 | PDCD1 (1.00) | PDCD1CD274 | |
| Evixapodlin SCHEMBL29387636 | 0.83 | PDCD1 (1.00) | PDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402917-A1 | COMPOUND AS SMALL MOLECULE INHIBITOR PD-1/PD-L1 AND APPLICATION THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2022-12-22 | — | — | US | disclosed |
| EP-4043461-A1 | COMPOUND AS SMALL MOLECULE INHIBITOR PD-1/PD-L1 AND APPLICATION THEREOF | Medshine Discovery Inc. (CN) | 2022-08-17 | — | — | EP | disclosed |
| WO-2021063404-A1 | COMPOUND AS SMALL MOLECULE INHIBITOR PD-1/PD-L1 AND APPLICATION THEREOF | 南京明德新药研发有限公司 | 2021-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402917-A1 | COMPOUND AS SMALL MOLECULE INHIBITOR PD-1/PD-L1 AND APPLICATION THEREOF | CD274, PDCD1, PDCD1LG2 | PDCD1 2/4885CD274 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.